Form 4: Syros Pharmaceuticals Director Akkaraju Srinivas Reports Stock Option and RSU Grant

Director Akkaraju Srinivas of Syros Pharmaceuticals reports the acquisition of stock options and restricted stock units (RSUs) on June 5, 2024.

Summary

• On June 5, 2024, Akkaraju Srinivas, a director of Syros Pharmaceuticals, reported the acquisition of stock options and restricted stock units.
• The stock options grant allows the director to purchase 6,000 shares of common stock at an exercise price of $5.30 per share.
• These options vest starting six months after the grant date, with 50% vesting on the six-month anniversary and the remainder vesting monthly until the first anniversary, contingent upon continued service as a director.
• Additionally, the director received 4,000 restricted stock units (RSUs), each representing the right to receive one share of Syros Pharmaceuticals' common stock.
• These RSUs will vest entirely on the earlier of the first anniversary of the grant date or the date of the company's next Annual Meeting of Stockholders, also contingent upon continued service as a director.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The granting of stock options and RSUs is a standard practice that aligns the director's interests with those of the shareholders. The vesting schedule encourages continued service.

Positives

• The grant of stock options and RSUs to a director aligns their interests with those of the shareholders, incentivizing them to work towards the company's success.
• The vesting schedules for both the stock options and RSUs encourage continued service and commitment from the director.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting of the options and RSUs is contingent upon the director's continued service.

Industry Context

Granting stock options and RSUs to directors is a common practice in the pharmaceutical industry to align management's interests with those of shareholders and incentivize long-term value creation.

Comparison to Industry Standards

• Stock option and RSU grants are standard compensation practices for directors in publicly traded companies, particularly in the biotech and pharmaceutical sectors.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize similar equity-based compensation to incentivize their directors and align their interests with shareholders.
• The vesting schedules described are also typical, with vesting periods ranging from one to four years, contingent on continued service.

Stakeholder Impact

• Shareholders may view the grant of stock options and RSUs positively, as it aligns the director's interests with the company's long-term success.
• The director is incentivized to contribute to the company's growth and profitability to increase the value of their stock options and RSUs.

Key Dates

Keywords

Syros Pharmaceuticals, Director, Stock Options, Restricted Stock Units, RSU, Beneficial Ownership, Form 4, Akkaraju Srinivas